The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand Factor (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF/FVIII in healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Ay, Cihan, Kovacevic, Katarina D., Kraemmer, Daniel, Schoergenhofer, Christian, Gelbenegger, Georg, Firbas, Christa, Quehenberger, Peter, Jilma-Stohlawetz, Petra, Gilbert, James C., Zhu, Shuhao, Beliveau, Martin, Koenig, Franz, Iorio, Alfonso, Jilma, Bernd, Derhaschnig, Ulla, Pabinger, Ingrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651782/
https://www.ncbi.nlm.nih.gov/pubmed/36108308
http://dx.doi.org/10.1182/blood.2022016571

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651782/
https://www.ncbi.nlm.nih.gov/pubmed/36108308
http://dx.doi.org/10.1182/blood.2022016571

Ejemplares similares